INTRODUCTION AND OBJECTIVES:
Stage III renal cell carcinoma (RCC) encompasses both node-positive (pT1-3N1M0) and node-negative (pT3N0M0) disease. However, prior institutional studies have indicated that among Stage III patients, those with nodal disease have significantly worse oncologic outcomes. Instead they experience survival similar to patients with Stage IV disease. Our study aims to validate these findings using a large, nationally representative sample of kidney cancer patients in order to further inform current RCC staging.
METHODS CONCLUSIONS: Current staging by the American Joint Committee on Cancer groups pT1-3N1M0 and pT3N0M0 as Stage III disease. However, our validation study e in agreement with prior smaller institutional studies e suggests the need for further stratification and even placement of pT1-3N1M0 patients into Stage IV. Pathologic staging that accurately reflects oncologic prognosis may help clinicians better counsel and select patients who will derive the most benefit from lymphadenectomy, adjuvant systemic therapy, and more rigorous imaging surveillance.
